Comparison of pregnancy outcome after adding oral or intramuscular progesterone to vaginal progesterone in frozen embryo transfer: A cross-sectional study.

IF 1.6 Q3 OBSTETRICS & GYNECOLOGY
International Journal of Reproductive Biomedicine Pub Date : 2024-12-02 eCollection Date: 2024-10-01 DOI:10.18502/ijrm.v22i10.17661
Sahereh Arabian, Maryam Eftekhar, Saeideh Dashti, Nahid Homayoon, Elham Nikfarjam
{"title":"Comparison of pregnancy outcome after adding oral or intramuscular progesterone to vaginal progesterone in frozen embryo transfer: A cross-sectional study.","authors":"Sahereh Arabian, Maryam Eftekhar, Saeideh Dashti, Nahid Homayoon, Elham Nikfarjam","doi":"10.18502/ijrm.v22i10.17661","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Currently, frozen embryo transfers (FET) account for 41% of all embryo transfer cycles. Vaginal progesterone preparations have become the leading choice for luteal phase support due to their convenient application; however, using only vaginal progesterone during FET cycles results in a lower ongoing pregnancy rate.</p><p><strong>Objective: </strong>This study aimed to investigate whether replacing intramuscular (IM) progesterone with oral dydrogesterone in FET cycles affects pregnancy outcomes or not.</p><p><strong>Materials and methods: </strong>In this cross-sectional study, pregnancy outcomes were analyzed in women who underwent cleavage stage FET during an endometrial preparation cycle using hormone replacement therapy at Yazd Reproductive Sciences Institute, Yazd, Iran, between April 2023 and November 2023. The study examined 2 groups based on a luteal phase support regimen: the dydrogesterone group, which received vaginal progesterone and oral dydrogesterone, and the IM progesterone group, which received vaginal progesterone and IM progesterone. Data were extracted from patient files to compare outcomes between the 2 groups.</p><p><strong>Results: </strong>A total of 960 cycles meeting the inclusion criteria were analyzed, with 292 women in the dydrogesterone group and 668 women in the IM progesterone group, and pregnancy outcomes were compared between the 2 groups. The chemical pregnancy rates (28.4% vs. 29.9%, p = 0.636), clinical pregnancy rates (25.3% vs. 26.9%, p = 0.604), and ongoing pregnancy rates (21.9% vs. 23.8%, p = 0.525) were lower and miscarriage rates (14.7% vs. 11.7%, p = 0.210) were higher in dydrogesterone group compared to IM progesterone group, although this difference was not statistically significant.</p><p><strong>Conclusion: </strong>Based on the ease of use and similar pregnancy outcomes of oral dydrogesterone, it can potentially replace the daily injections of IM progesterone.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"22 10","pages":"763-770"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788660/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Reproductive Biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijrm.v22i10.17661","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Currently, frozen embryo transfers (FET) account for 41% of all embryo transfer cycles. Vaginal progesterone preparations have become the leading choice for luteal phase support due to their convenient application; however, using only vaginal progesterone during FET cycles results in a lower ongoing pregnancy rate.

Objective: This study aimed to investigate whether replacing intramuscular (IM) progesterone with oral dydrogesterone in FET cycles affects pregnancy outcomes or not.

Materials and methods: In this cross-sectional study, pregnancy outcomes were analyzed in women who underwent cleavage stage FET during an endometrial preparation cycle using hormone replacement therapy at Yazd Reproductive Sciences Institute, Yazd, Iran, between April 2023 and November 2023. The study examined 2 groups based on a luteal phase support regimen: the dydrogesterone group, which received vaginal progesterone and oral dydrogesterone, and the IM progesterone group, which received vaginal progesterone and IM progesterone. Data were extracted from patient files to compare outcomes between the 2 groups.

Results: A total of 960 cycles meeting the inclusion criteria were analyzed, with 292 women in the dydrogesterone group and 668 women in the IM progesterone group, and pregnancy outcomes were compared between the 2 groups. The chemical pregnancy rates (28.4% vs. 29.9%, p = 0.636), clinical pregnancy rates (25.3% vs. 26.9%, p = 0.604), and ongoing pregnancy rates (21.9% vs. 23.8%, p = 0.525) were lower and miscarriage rates (14.7% vs. 11.7%, p = 0.210) were higher in dydrogesterone group compared to IM progesterone group, although this difference was not statistically significant.

Conclusion: Based on the ease of use and similar pregnancy outcomes of oral dydrogesterone, it can potentially replace the daily injections of IM progesterone.

冷冻胚胎移植中口服或肌肉注射黄体酮与阴道黄体酮的妊娠结局比较:一项横断面研究。
背景:目前,冷冻胚胎移植(FET)占所有胚胎移植周期的41%。阴道黄体酮制剂因其应用方便而成为黄体期支持的首选;然而,在FET周期中仅使用阴道黄体酮会导致较低的持续妊娠率。目的:本研究旨在探讨在FET周期中口服地屈孕酮替代肌内注射(IM)黄体酮是否会影响妊娠结局。材料和方法:在这项横断面研究中,分析了2023年4月至2023年11月在伊朗Yazd生殖科学研究所进行的子宫内膜准备周期中使用激素替代疗法进行卵裂期FET的妇女的妊娠结局。该研究根据黄体期支持方案对两组进行了研究:地屈孕酮组,接受阴道孕酮和口服地屈孕酮;注射孕酮组,接受阴道孕酮和注射孕酮。从患者档案中提取数据,比较两组的结果。结果:共分析960例符合纳入标准的周期,地屈孕酮组292例,IM孕酮组668例,比较两组妊娠结局。地屈孕酮组化学妊娠率(28.4%比29.9%,p = 0.636)、临床妊娠率(25.3%比26.9%,p = 0.604)、持续妊娠率(21.9%比23.8%,p = 0.525)低于IM孕酮组,流产率(14.7%比11.7%,p = 0.210)高于IM孕酮组,但差异无统计学意义。结论:口服地屈孕酮使用方便,妊娠结局相似,有替代每日注射IM孕酮的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
7.70%
发文量
93
审稿时长
16 weeks
期刊介绍: The International Journal of Reproductive BioMedicine (IJRM), formerly published as "Iranian Journal of Reproductive Medicine (ISSN: 1680-6433)", is an international monthly scientific journal for who treat and investigate problems of infertility and human reproductive disorders. This journal accepts Original Papers, Review Articles, Short Communications, Case Reports, Photo Clinics, and Letters to the Editor in the fields of fertility and infertility, ethical and social issues of assisted reproductive technologies, cellular and molecular biology of reproduction including the development of gametes and early embryos, assisted reproductive technologies in model system and in a clinical environment, reproductive endocrinology, andrology, epidemiology, pathology, genetics, oncology, surgery, psychology, and physiology. Emerging topics including cloning and stem cells are encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信